We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+14.67%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.63B
AUM Growth
+$404M
(+18%)
Cap. Flow
+$126M
Cap. Flow
% of AUM
4.79%
Top 10 Holdings %
Top 10 Hldgs %
47.42%
Holding
84
New
20
Increased
43
Reduced
13
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$64.6M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$35.6M |
| 3 |
AGN
Allergan plc
AGN
|
+$33.5M |
| 4 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$26.6M |
| 5 |
Biogen
BIIB
|
+$23.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$76.2M |
| 2 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$58.1M |
| 3 |
Amgen
AMGN
|
+$36.4M |
| 4 |
AGN
Allergan Inc
AGN
|
+$34.6M |
| 5 |
PTC Therapeutics
PTCT
|
+$23.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVO
51
Novo Nordisk
NVO
$228B
| $10.4M | 0.39% |
389,550
+18,980
| +5% | +$437K |
|
52
Cigna
CI
$78.4B
| $9.9M | 0.38% |
+76,465
| New | +$8.89M |
|
|
ZSPH
53
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $9.23M | 0.35% |
219,303
+171,408
| +358% | +$7.84M |
|
54
Universal Health Services
UHS
$10.2B
| $7.76M | 0.29% |
65,939
+4,273
| +7% | +$473K |
|
55
TG Therapeutics
TGTX
$8.19B
| $6.75M | 0.26% |
+436,084
| New | +$6.6M |
|
|
ADXS
56
DELISTED
Advaxis Inc
ADXS
| $2.17M | 0.08% |
10,044
-4,013
| -29% | -$617K |
|
57
Accuray
ARAY
$27.5M
| $2.11M | 0.08% |
227,195
+895
| +0.4% | +$7.13K |
|
|
IPXL
58
DELISTED
Impax Laboratories, Inc.
IPXL
| $1.86M | 0.07% |
+39,697
| New | +$1.58M |
|
|
LCI
59
DELISTED
Lannett Company, Inc.
LCI
| $1.74M | 0.07% |
+6,409
| New | +$1.46M |
|
|
ENDP
60
DELISTED
Endo International plc
ENDP
| $1.68M | 0.06% |
+18,688
| New | +$1.56M |
|
61
Jazz Pharmaceuticals
JAZZ
$16.1B
| $1.63M | 0.06% |
+9,405
| New | +$1.61M |
|
62
Bausch Health
BHC
$1.75B
| $1.61M | 0.06% |
8,101
+6,301
| +350% | +$1.12M |
|
63
McKesson
MCK
$104B
| $1.58M | 0.06% |
+6,995
| New | +$1.55M |
|
|
WX
64
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
| $1.58M | 0.06% |
40,653
+280
| +0.7% | +$10.8K |
|
|
CYTO
65
DELISTED
Altamira Therapeutics Ltd
CYTO
| $1.5M | 0.06% |
+3
| New | +$1.21M |
|
|
IMDZ
66
DELISTED
Immune Design Corp.
IMDZ
| $1.42M | 0.05% |
67,127
+45,946
| +217% | +$1.2M |
|
67
Tandem Diabetes Care
TNDM
$1.27B
| $1.41M | 0.05% |
11,142
-2,000
| -15% | -$260K |
|
68
Alkermes
ALKS
$8.11B
| $1.39M | 0.05% |
+22,770
| New | +$1.56M |
|
|
HZNP
69
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $1.34M | 0.05% |
+51,476
| New | +$944K |
|
70
Pacira BioSciences
PCRX
$1.04B
| $1.24M | 0.05% |
+13,939
| New | +$1.41M |
|
|
ASRT
71
DELISTED
Assertio
ASRT
| $1.22M | 0.05% |
+911
| New | +$1.12M |
|
|
CARM
72
DELISTED
Carisma Therapeutics
CARM
| $1M | 0.04% |
5,624
| – | – |
|
|
EGRX
73
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $927K | 0.04% |
+22,123
| New | +$628K |
|
74
Nektar Therapeutics
NKTR
$2.39B
| $870K | 0.03% |
+5,274
| New | +$1.08M |
|
|
CBM
75
DELISTED
Cambrex Corporation
CBM
| $463K | 0.02% |
+11,673
| New | +$345K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q1 2015 Portfolio in Review
As of Q1 2015, Sectoral Asset Management held 84 positions worth $2.63B, up 18% from $2.23B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Sectoral Asset Management deployed $126M of net new capital in Q1 2015, opening 20 new positions and adding to 43 existing holdings. Its largest new stake was Tetraphase Pharmaceuticals, Inc.: 30,270 shares worth $22.2M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.
On the sell side, the largest reduction was Amgen, an estimated $36.4M trimmed.
- Sectoral Asset Management's largest Q1 2015 buy was Tetraphase Pharmaceuticals, Inc.: 30,270 shares worth $22.2M.
- Sectoral Asset Management added most to Gilead Sciences in Q1 2015, an estimated $64.6M increase.
- Sectoral Asset Management's biggest Q1 2015 reduction was Amgen, cutting an estimated $36.4M.
- Sectoral Asset Management fully exited Regeneron Pharmaceuticals in Q1 2015, selling an estimated $76.2M.
- Sectoral Asset Management's ten largest holdings make up 47% of its $2.63B portfolio in Q1 2015.
- Sectoral Asset Management opened 20 new positions and closed 7 in Q1 2015.
- Sectoral Asset Management's portfolio value rose 18% quarter-over-quarter to $2.63B.
Based on Sectoral Asset Management's 13F filing for Q1 2015, filed 14 May 2015.